Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.

Insulinaemic potential of diet linked to colorectal cancer risk

13 Sep 2018

A recent study suggests that the influence of dietary intake on the development of colorectal cancer is partly caused by dietary insulinaemic potential.

Associations between hyperinsulinaemic diets and colorectal cancer risk were assessed using an empirical dietary index for hyperinsulinaemia (EDIH), a food-based index that characterizes dietary insulinaemic potential based on circulating C-peptide concentrations.

Using food-frequency questionnaires, the investigators evaluated diet in 46,210 men (Health Professionals Follow-Up Study, 1986–2012) and 74,191 women (Nurses’ Health Study, 1984–2012) to calculate EDIH scores.

A total of 2,683 incident colorectal cancer cases were identified over 26 years of follow-up. Comparing participants in the highest vs those in the lower quintiles, higher EDIH scores in men, women, and both men and women were associated with 33 percent (hazard ratio [HR], 1.33; 95 percent CI, 1.11–1.61; p=0.0005), 22 percent (HR, 1.22; 1.03–1.45; p=0.01) and 26 percent (pooled HR, 1.26; 1.2–1.42; p<0.0001) higher risk of developing colorectal cancer, respectively.

While such associations were limited to the distal colon and rectum in men and to the distal and proximal colon in women, combined risk estimates remained significant for all anatomic locations except for the rectum.

Comparing participants in extreme EDIH quintiles, no significant association was observed for proximal colon cancer in men (HR, 1.15; 0.84–1.57; p=0.32). However, there was an increased risk for distal colon (HR, 1.63; 1.14–2.32; p=0.002) and rectal (HR, 1.63; 1.09–2.44; p=0.01) cancer. The risk in women was heightened for proximal (HR, 1.28; 1.00–1.63; p=0.03) and distal (HR, 1.46; 1.05–2.03; p=0.03) colon cancer but not for rectal cancer (HR, 0.88; 0.60–1.29; p=0.61).

“Insulin response may be important in colorectal cancer development. Diet modulates insulin response and may be a modifiable factor in colorectal cancer prevention,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.